Startups, philanthropy, billionaires, academia, neuromodulation, psychedelics, AI and new therapies in bipolar, autism, and Parkinson’s with Rob Malenka
Business Trip by PsyMed Ventures, a podcast exploring the future of mental and brain health & the startups building it
Welcome back to Business Trip by PsyMed Ventures, a podcast exploring the future of mental and brain health & the startups building it! 🧠
Matias interviews Rob Malenka, Chief Scientific Officer of Bayshore Global Management, the family office of Google co-founder Sergey Brin. Bayshore has played a major role in advancing treatments for Parkinson's, bipolar, and autism.
In this episode, we discuss:
Why progress in psychiatry is slow because the brain is the most complex organ and many disorders are highly heterogeneous
The bottlenecks including weak replicability in research, academic politics, perverse incentives, and pharma’s avoidance of neuropsychiatry
How breakthroughs require early detection, rigorous science, and bridging academia with biotech through venture philanthropy
How success depends on mission-driven, ethical people who align science, capital, and patient impact
The opportunities in neuromodulation, data-driven precision medicine, and combination therapies
Listen to the episode here, on Spotify, or on Apple Podcasts.
Once you've finished the episode, we'd love to hear your thoughts! Tweet us at @psymedventures or email us at hi@psymed.ventures to share your views.
P.S. Do you know someone who would enjoy the Business Trip by PsyMed Ventures podcast? Feel free to share this newsletter by clicking the link below and hitting the ❤️ button on this post to help us reach more people on Substack 🙏